Adaptive Biotechnologies Corp. (ADPT)
24.08
-1.50
(-5.86%)
USD |
NASDAQ |
Oct 16, 15:01
Adaptive Biotechnologies SG&A Expense (TTM) : 180.38M for June 30, 2026
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 180.38M |
| March 31, 2026 | 174.16M |
| December 31, 2025 | 167.27M |
| September 30, 2025 | 162.86M |
| June 30, 2025 | 159.24M |
| March 31, 2025 | 156.10M |
| December 31, 2024 | 157.56M |
| September 30, 2024 | 160.57M |
| June 30, 2024 | 163.32M |
| March 31, 2024 | 171.29M |
| December 31, 2023 | 172.51M |
| September 30, 2023 | 176.02M |
| June 30, 2023 | 177.72M |
| March 31, 2023 | 177.03M |
| December 31, 2022 | 184.13M |
| September 30, 2022 | 188.03M |
| Date | Value |
|---|---|
| June 30, 2022 | 190.86M |
| March 31, 2022 | 184.66M |
| December 31, 2021 | 169.97M |
| September 30, 2021 | 151.87M |
| June 30, 2021 | 133.32M |
| March 31, 2021 | 120.61M |
| December 31, 2020 | 110.89M |
| September 30, 2020 | 99.78M |
| June 30, 2020 | 90.80M |
| March 31, 2020 | 79.79M |
| December 31, 2019 | 68.78M |
| September 30, 2019 | 47.96M |
| June 30, 2019 | 39.97M |
| March 31, 2019 | 24.41M |
| June 30, 2018 | 9.59M |
| March 31, 2018 | 9.59M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Personalis, Inc. | 67.03M |
| 10X Genomics, Inc. | 297.01M |
| Alamar Biosciences, Inc. (California) | 31.22M |
| Champions Oncology, Inc. | 21.81M |
| Medpace Holdings, Inc. | 189.02M |